Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease

Trial Profile

Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 25 Sep 2017

At a glance

  • Drugs Begelomab (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Sponsors ADIENNE
  • Most Recent Events

    • 20 Sep 2017 Status changed from active, no longer recruiting to discontinued.
    • 08 Jul 2017 This study has been completed in Spain.
    • 21 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top